BioLeap is a drug design company that leverages its proprietary technology platform to identify and optimize lead compounds where other approaches have not been successful.
Collaboration
BioLeap creates novel compounds with intellectual property protection, enhances the intellectual property estate around existing compounds, avoids obstructive patents, and generates fast-follower compounds for early market entry. Learn more about how our technology can help solve your drug discovery problems.
Technology
Unlike random screening approaches, BioLeap’s hypothesis-driven method is particularly effective for designing and improving lead compounds for ‘difficult’ targets where traditional methods have failed. BioLeap’s methodology create molecules of practically infinite structural diversity and accurately predicts their relative binding affinity to a target protein. Read More